GRI Projected Dividend Yield
GRI Bio Inc ( NASDAQ : GRI )GRI Bio is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of biopharmaceutical products. Co. is developing medications for central nervous system disorders with a focus on abuse-deterrent medications. Co.'s primary investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall®) for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the therapeutic benefit when taken orally. 25 YEAR PERFORMANCE RESULTS |
GRI Dividend History Detail GRI Dividend News GRI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2019 |
Dec 18, 2019 |
Dec 19, 2019 |
Dec 20, 2019 |
Dec 27, 2019 |
0.5113 |
2019 |
Sep 18, 2019 |
Sep 19, 2019 |
Sep 20, 2019 |
Sep 26, 2019 |
0.2705 |
2019 |
Jun 19, 2019 |
Jun 20, 2019 |
Jun 21, 2019 |
Jun 27, 2019 |
0.3725 |
2019 |
Mar 20, 2019 |
Mar 21, 2019 |
Mar 22, 2019 |
Mar 28, 2019 |
0.3464 |
2019 Total: |
1.5007 |